The British Association of Dermatologists (BAD) hosted its 106th Annual Meeting at the Manchester Central Convention Complex from June 30 to July 2. The event brought together dermatologists, researchers, scientists
The British College of Aesthetic Medicine (BCAM) has urged patients to prioritise safety when considering steroid injections for hay fever relief. BCAM shares that, following reports of growing popularity, some
Skincare company SkinCeuticals hosted press and practitioners to present its newly launched P-TIOX Cream and the next generation of PHYTO CORRECTIVE on July 14. The morning opened with David McNulty-Ringshaw,
Aesthetics attended the launch of Versatile Bronze Shade + Sculpt by skincare makeup brand et al., distributed by International Institute for Active Ageing (iiaa), at The Beauty Edit Mayfair on
Science-led beauty and longevity brand Vivorum welcomed specialist guests to The Beaumont Mayfair on July 16. The company said the intimate dinner was held to introduce Vivorum’s debut antiageing supplement,
Pharmaceutical company Evolus hosted an event at the Everyman Cinema for the launch of injectable hyaluronic acid Estyme on July 6. Opening the event, Dallas Waltham, marketing manager at Evolus
Aesthetic manufacturer VIVACY Laboratories hosted an event at its headquarters to mark the debut of its new calcium hydroxylapatite (CaHA) injectable, Novuma. Delegates attended an afternoon of networking alongside faculty
Biotechnology company Absci has released positive interim Phase 1 data from its first-in-human trial of investigational anti-prolactin receptor (PRLR) antibody ABS-201. The company details that ABS-201 is an experimental antibody
Pharmaceutical company Allergan Aesthetics, an AbbVie company, has announced that the European Commission has approved trenibotulinumtoxinE ‘Boey’ in Europe. The company shares that Boey is the first rapid-onset and short-duration
A comprehensive review, Botulinum Toxin A Myths, Evidence, and Global Media Narratives, published in Aesthetic Plastic Surgery has highlighted public misconceptions on botulinum toxin type A (BoNT-A). Researchers analysed 513 English-language sources